NasdaqGM:NTLABiotechs
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clinical Hold On Lead Gene Editing Trial
Why Intellia’s recent clinical hold matters for investors
Intellia Therapeutics (NTLA) recently halted dosing and patient enrollment in its late stage MAGNITUDE studies after a patient death linked to severe liver side effects, prompting an FDA clinical hold on its lead therapy candidate.
See our latest analysis for Intellia Therapeutics.
The clinical hold comes after a steep 90 day share price return decline of 58.69%, leaving Intellia at US$10.13. That setback contrasts with a positive year...